Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report

  • Received : 2012.07.04
  • Accepted : 2012.10.29
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. Materials and Methods: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. Results: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was $70.0{\pm}10.1$ years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. Conclusion: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.

Keywords

References

  1. Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 2011;69:e364-71. https://doi.org/10.1016/j.joms.2011.03.051
  2. Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST, Kolk A, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. J Craniomaxillofac Surg 2011;39:272-7. https://doi.org/10.1016/j.jcms.2010.05.009
  3. Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, et al. Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 2011;47:191-4. https://doi.org/10.1016/j.oraloncology.2010.11.007
  4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34. https://doi.org/10.1016/j.joms.2004.02.004
  5. Park HM, Lee ES, Kim SM. The use of osteoporosis medications in Korea in 2008. J Bone Metab 2009;16:87-93.
  6. Ko JM, Kim KS. Guidelines for diagnosis and treatment of osteoporosis. Seoul: Sehung Dublishing; 2008.
  7. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  8. Choi BJ, Kwon YD, Lee B, Walter C, Al-Nawas B. Maxillary sinusitis as a complication of oral bisphosphonate related osteonecrosis of the jaw: a case report. J Korean Assoc Oral Maxillofac Surg 2009;35:39-40.
  9. Kim KW, Kim BJ, Lee CH. Clinical study of diagnosis and treatment of bisphosphonate-related osteonecrosis of the jaws. J Korean Assoc Oral Maxillofac Surg 2011;37:54-61. https://doi.org/10.5125/jkaoms.2011.37.1.54
  10. Son HJ, Jang HY, Keum YS, Lee JY, Kim HC, Lee SC. Oral bisphosphonates induced osteonecrosis of the mandible: a case report. J Korean Assoc Oral Maxillofac Surg 2009;35:106-11.
  11. Han YS, Lee IW, Lee H, Suh JW, Kim SM, Myoung H, et al. Retrospective study on the bisphosphonate-related osteonecrosis of jaw. J Korean Assoc Oral Maxillofac Surg 2011;37:470-6. https://doi.org/10.5125/jkaoms.2011.37.6.470
  12. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36. https://doi.org/10.1359/jbmr.080205
  13. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  14. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. https://doi.org/10.1200/JCO.2005.02.8670
  15. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.
  16. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. https://doi.org/10.1359/jbmr.0707onj
  17. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7. https://doi.org/10.1016/j.bone.2008.01.003
  18. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. https://doi.org/10.1016/j.joms.2006.10.061
  19. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al; Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-53. https://doi.org/10.1016/j.joms.2009.03.050
  20. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010;28:365-83. https://doi.org/10.1007/s00774-010-0162-7
  21. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008;36:95-103. https://doi.org/10.1016/j.jcms.2007.06.008
  22. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007;86:1022-33. https://doi.org/10.1177/154405910708601102
  23. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997;12:1700-7. https://doi.org/10.1359/jbmr.1997.12.10.1700
  24. Korea Centers for Disease Control and Prevention [Internet]. Ministry for Health, Welfare and Family Affairs, Korean National Health and Nutrition Examination Survey in 2005 [cited 2012 Jul 1]. Available from: http://knhanes.cdc.go.kr.
  25. Choi HJ, Shin CS, Ha YC, Jang S, Jang S, Park C, et al. Burden of osteoporosis in adults in Korea: a national health insurance database study. J Bone Miner Metab 2012;30:54-8. https://doi.org/10.1007/s00774-011-0280-x
  26. Jang S, Park C, Jang S, Yoon HK, Shin CS, Kim DY, et al. Medical service utilization with osteoporosis. Endocrinol Metab 2010;25:326-39. https://doi.org/10.3803/EnM.2010.25.4.326
  27. Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 2013;24:707-11. https://doi.org/10.1007/s00198-012-2016-8
  28. The Korean Endocrine Society, The Korean Society of Bone Metabolism, The Korean Society of Osteoporosis, The Korean Association of Oral and Maxillofacial Surgeons. Bisphosphonate related osteonecrosis of the jaw (BRONJ)-position statement of Korea. J Korean Endocr Soc 2009;24:227-30. https://doi.org/10.3803/jkes.2009.24.4.227

Cited by

  1. Preventive Effect of Crocin on Osteoporosis in an Ovariectomized Rat Model vol.2014, pp.None, 2013, https://doi.org/10.1155/2014/825181
  2. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw vol.16, pp.None, 2013, https://doi.org/10.1186/s12903-016-0290-0
  3. Pharmacologic treatment of osteoporosis vol.59, pp.11, 2016, https://doi.org/10.5124/jkma.2016.59.11.847
  4. Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males vol.5, pp.1, 2013, https://doi.org/10.1186/s40064-016-3138-9
  5. Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition vol.5, pp.1, 2013, https://doi.org/10.3390/dj5010013
  6. Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients vol.9, pp.None, 2013, https://doi.org/10.3389/fphar.2018.00796
  7. Viewpoints of dentists on the use of bisphosphonates in rheumatology patients vol.68, pp.4, 2013, https://doi.org/10.1111/idj.12363
  8. Regenerative effect of recombinant human bone morphogenetic protein-2/absorbable collagen sponge (rhBMP-2/ACS) after sequestrectomy of medication-related osteonecrosis of the jaw (MRONJ) vol.46, pp.3, 2020, https://doi.org/10.5125/jkaoms.2020.46.3.191
  9. Surgical Treatment of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study vol.17, pp.23, 2013, https://doi.org/10.3390/ijerph17238801
  10. Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw vol.36, pp.5, 2021, https://doi.org/10.3803/enm.2021.1170
  11. Advanced Peri-Implantitis and Implant Removal as Risk Factors for Osteonecrosis of the Jaw in Patients on Oral Bisphosphonate Therapy vol.47, pp.5, 2013, https://doi.org/10.1563/aaid-joi-d-20-00298
  12. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons vol.28, pp.4, 2013, https://doi.org/10.11005/jbm.2021.28.4.279